The FDA granted accelerated approval to Ascendis Pharma’s once‑weekly TransCon CNP (Yuviwel) for children with achondroplasia, clearing the company to compete with BioMarin’s Voxzogo. The decision was based on improvements in annualized growth velocity (AGV) and includes post‑marketing confirmatory requirements to verify clinical benefit. Ascendis received a rare pediatric disease priority review voucher alongside the approval and plans a Q2 commercial rollout. Analysts see modest 2026 uptake with potential acceleration in 2027 as EU filings and label expansions progress. The approval shifts the treatment landscape for achondroplasia by adding a less frequent dosing option, forcing clinicians and payers to weigh convenience and long‑term safety data across newly competitive therapies.